Lupin receives USFDA approval to market Etabonate Ophthalmic Suspension, a generic treatment for seasonal allergic conjunctivitis. The drug is a generic equivalent of Bausch & Lomb's Lotemax.
New Delhi, Apr 25 (PTI) Drug maker Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat certain eye conditions.
The company has received approval from the US Food and Drug Administration (USFDA) to market Etabonate Ophthalmic Suspension, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Bausch & Lomb Inc's Lotemax ophthalmic suspension (0.5 per cent), it added.
Loteprednol Etabonate ophthalmic suspension, 0.5 per cent, is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
As per the IQVIA MAT data, the product had estimated annual sales of USD 59 million in the US.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback